Phase 3 trial into new cutaneous T-cell lymphoma treatment posts positive results

The Phase 3 ALCANZA clinical trial into the drug brentuximab vedotin (Adcetris) has posted positive results, Takeda Pharmaceutical and Seattle Genetics have announced. The drug, which is for the treatment of cutaneous T-cell lymphoma (CTCL), met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response (ORR4) lasting at least four months. The randomised trial compared the use of single-agent brentuximab vedotin to a control arm of investigator’s choice of standard therapies, methotrexate or bexarotene, in 131 patients with CD30-expressing CTCL who received prior systemic or radiation therapy. The results of the ALCANZA trial demonstrated